Novartis Ag (NVS) Retained Earnings (2009 - 2026)
Novartis Ag (NVS) posted Retained Earnings of $40.9 billion for Q2 2026, down 10.04% sequentially from $45.4 billion in Q4 2025, and down 0.96% YoY from $41.3 billion in Q2 2025.
Novartis Ag (NVS) Retained Earnings (2009 - 2026) Analysis & Trends
Novartis Ag has reported Retained Earnings for 18 years, with the latest figure at $40.9 billion in Q2 2026.
- Quarterly Retained Earnings fell 0.96% year-over-year to $40.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $40.9 billion (down 0.96% YoY) and the FY2025 annual result came in at $45.4 billion, up 4.87% from the prior year.
- Retained Earnings eased to $40.9 billion in Q2 2026 per NVS's latest filing, from $45.4 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $62.1 billion in Q2 2022 and troughed at $40.9 billion in Q2 2026.
- A 5-year average of $47.7 billion and a median of $45.4 billion in 2025 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings increased 16.73% in 2022, then decreased 21.63% in 2023.
- Over 5 years, Retained Earnings stood at $58.5 billion in 2022, then fell by 21.63% to $45.9 billion in 2023, then fell by 5.62% to $43.3 billion in 2024, then rose by 4.87% to $45.4 billion in 2025, then dropped by 10.04% to $40.9 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $40.9 billion, $45.4 billion, and $41.3 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 469.84 Bn | 463.27 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 378.23 Bn | 371.09 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 303.01 Bn | 295.32 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 258.57 Bn | 253.67 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 237.36 Bn | 223.37 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 183.27 Bn | 180.09 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 160.74 Bn | 149.04 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 105.88 Bn | 101.72 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Sanofi | 55.28 Bn | 47.90 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.86 Bn |
| Dec 31, 2025 | 45.41 Bn |
| Jun 30, 2025 | 41.25 Bn |
| Dec 31, 2024 | 43.31 Bn |
| Jun 30, 2024 | 40.97 Bn |
| Dec 31, 2023 | 45.88 Bn |
| Jun 30, 2023 | 51.06 Bn |
| Dec 31, 2022 | 58.54 Bn |
| Jun 30, 2022 | 62.10 Bn |
| Dec 31, 2021 | 66.80 Bn |
| Jun 30, 2021 | 53.19 Bn |
| Dec 31, 2020 | 55.74 Bn |
| Jun 30, 2020 | 52.94 Bn |
| Dec 31, 2019 | 54.62 Bn |
| Jun 30, 2019 | 50.56 Bn |
| Dec 31, 2018 | 77.74 Bn |
| Jun 30, 2018 | 75.93 Bn |
| Dec 31, 2017 | 73.30 Bn |
| Dec 31, 2016 | 73.94 Bn |
| Dec 31, 2015 | 76.16 Bn |